Bård Røsok

HPB surgeon and bicycle fanatic with interest in arts, design and US and international politics

[Bård Røsok @RoesokMD]

@sparrelid @karolinskainst @KarolinskaUnsju @HpbKarolinska @EAHPBA @ssmfgrants @IhreLundg @MagnusNsurgonc @hpbjournal @hpb_so @poyaghorbani @Gio_Marchegiani @chiaro_del @MarcBesselink Congratulations Ernesto. Honours well deserved.

[Bård Røsok @RoesokMD]

@villesallinen Thank you for a great meeting @villesallinen

[Bård Røsok @RoesokMD]

@timpawlik So sorry for your loss, Tim. My sincere condolences 💐

[Bård Røsok @RoesokMD]

@MarcBesselink @SWexner @AmerSurg @AnnalsofSurgery Congrats, Marc. Truly well deserved👍🏻

[Flavio G Rocha, MD, FACS, FSSO @FlavioRochaMD]

Many 🙏🏼 to the @Oslounivsykehus #HPB unit
for a wonderful visit and opportunity to share
our work @OHSUsurgery @OHSUKnight
Impressed by breadth and scope of your team
and design of clinical trials to improve outcomes
To @visitBergen for Nordic #HPB 🇳🇴 🇸🇪 🇩🇰 🇫🇮

[Bård Røsok @RoesokMD]

@sapisochin @UHN @UHNTransplant @UHN_Surgery @uhnfoundation Congratulations, my friend. Well deserved!

[Bård Røsok @RoesokMD]

@michael_lidsky @DukeSurgOnc @DukeSurgery @allankirk11 @PeterAllenMD @blazer_trey @Sabino_Zani Congrats, Mike. Well deserved👍🏻

[Bård Røsok @RoesokMD]

@timpawlik @ElsevierConnect @GyasiSamilia @OhioStateSurg @OSUCCC_James @OhioStateMed @OSUWexMed @OhioState @OhioStateNews @SocSurgOnc @AHPBA @SSATNews @IHPBA Congratulations for a great achievement on an important topic, Tim & co-editors Well done!

[ILCA @ILCAnews]

This Liver Cancer Awareness Month, European and global organisations are united under the call for greater focus on prevention and early detection🎗️💚

#livercancerawarenessmonth

@EASLnews @EuropeLiver @digestivecancer

[Bård Røsok @RoesokMD]

@Abuhilal9Abu @IHPBA @EAHPBA @MarcBesselink @maarten_korrel @JonyvanHilst @hpb_so @PancreasVerona @poliambulanza @MyUniSR @StefanoCrippa6 @sassomarconi11 @iisifrigerio @AAFretland @SalviaRobi @PancreaticCanUK @PancreasClub Congrats Mo & @MarcBesselink Big kudos to you both for this important initiative. (and… you’re welcome..😉)

[TheLiverDoc™ @theliverdoc]

Big news in the field of Hepatology

In 1980, Jurgen Ludwig and his colleagues at Mayo Clinic, identified a severe type of fatty liver disease in people who did not drink signficant amounts of alcohol. The disease was more common in women, most patients were obese and suffered from diabetes.

No journal would accept their findings and the new name they gave the disease at the time, for a very long time and the paper got rejected multiple times.

They called it NASH, short for non-alcoholic fatty liver disease - the most severe form of NAFLD - or non-alcoholic fatty liver disease. https://t.co/Og3vJ0WMfA

Forget the 3816 times the paper has been cited in medical literature since, but these two terms are so well-known and commonly used even among the non-medical community that it is argualby the most common-reason consultation in a liver outpatient clinic in the current era.

But the Hepatology societies thought the term was kind of stigmatizing - one, it centered around not using alcohol signficantly (alcoholic is not a nice term) and also impossed the term 'fatty' on patients, which was kind of "judgemental," with negativity.

Thus, a transparent and collaborative Nomenclature Development Initiative process was started in 2020 with multiple global hepatology and gastroenterology societies, patients and patient advocacy organizations, regulators and industry representatives. A total of 236 panellists from 56 countries participated in four online surveys and two hybrid meetings.

Yesterday, after almost 41 years in existence, the term NAFLD and NASH was retired.

The new kids on the block are here.
Please meet them.

It is no more fatty liver disease - it is steatotic liver disease or SLD

It is no more NAFLD - but MASLD or metabolic dysfunction-associated steatotic liver disease.
MASLD is identified when patients who have hepatic (liver) steatosis (at least 5% liver cells should have fat deposit) and have at least one of five cardiometabolic risk factors without signficant alcohol consumption.

Metabolic dysfunction-associated steatohepatitis (MASH) is the replacement term for NASH.

But what if they have alcohol consumption which is inbetween insignficant consumption and signficiant consumption?
New category: MetALD - to describe those with MASLD who consume greater amounts of alcohol per week (140 g/week and 210 g/week for females and males respectively).

Those with no metabolic parameters and no known cause have "cryptogenic SLD."

This seminal paper and the rigorous scientific method which was followed to come to new terminologies is now available to read for free in the influential journal @HEP_Journal #LiverTwitter #MedTwitter

Read more on it here: https://t.co/HjyZw8KdVJ

[Bård Røsok @RoesokMD]

@OJNilsen Tour de finance ble omtalt i DN første gang 1. juli 2006, mens den første registrerte Strava aktivitet er datert 12. april 2008, så begrepet eksisterte nok før Strava-segmentet ble etablert.

[Bård Røsok @RoesokMD]

@MarcBesselink @EhPba @iisifrigerio @AAFretland @Gio_Marchegiani @berrevoet @JorgKleeff @Abuhilal9Abu @TomGallagherHPB @ksoreide @EAHPBA @IHPBA @EurPancClub @amsterdamumc @DPCG_official @pancreatitis_nl Congratulations, Marc. A well deserved honour👍🏻

[Åsmund A. Fretland @AAFretland]

@knutjla presenting #norpact1 at #ASCO23 : No survival benefit of neoadjuvant folforinox in resectable pancreatic cancer in Nordic multicenter population based trial, in ITT and per protocol population! 💣@Oslounivsykehus @xtofero @ksoreide @sparrelid @IHPBA @EAHPBA @AHPBA

[Bård Røsok @RoesokMD]

@TorzilliGuido @SSATNews @VautheyMD @TsengJennifer Well deserved Guido. You are a true master👍🏻

[Bård Røsok @RoesokMD]

Thank you @marjo_koskela and Minna Nortunen for giving us the oppurtunity to meet colleagues from all over Finland for the first laparoscopic liver meeting in Oulo. Prepares the way for future collaboration. @villesallinen @AAFretland @AghayanDavit @BjrnEdwin1

[Anita Balakrishnan @HPBCambridge]

Proud to share the results of the largest series on the #surgicaloutcomes of #gallbladdercancer to date - 3676 patients across 133 centres in 41 countries. Huge effort across @EAHPBA @IHPBA @ahpba Impossible without the help of our collaborators 🙏🙏https://t.co/uHSbOKIGqj

[Bård Røsok @RoesokMD]

@HPBCambridge @EAHPBA @IHPBA @AHPBA Congratulation for collecting this extensive and remarcable material for a rare and devastating disease. Impressive work with very interesting results. 👏🏻👍🏻

[Bård Røsok @RoesokMD]

@hcpommergaard Gratulerer👍

[Morten Hagness @HagnessMorten]

Å få ned ventelistene for organtransplantasjoner er en lavthengende frukt. Vi trenger en nasjonal koordinerende organisasjon, et fungerende register og god støtte til donorsykehusene. Det er god økonomi i å fikse dette! Morten Skauby @organdonasjon @arendalsuka #livetigave